Aratana Therapeutics Inc (PETX) Expected to Announce Quarterly Sales of $5.70 Million

Brokerages forecast that Aratana Therapeutics Inc (NASDAQ:PETX) will announce $5.70 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Aratana Therapeutics’ earnings. The highest sales estimate is $6.20 million and the lowest is $5.20 million. Aratana Therapeutics reported sales of $6.16 million during the same quarter last year, which indicates a negative year-over-year growth rate of 7.5%. The business is scheduled to issue its next earnings report on Thursday, November 1st.

On average, analysts expect that Aratana Therapeutics will report full-year sales of $26.80 million for the current fiscal year, with estimates ranging from $20.50 million to $38.10 million. For the next financial year, analysts expect that the company will report sales of $47.57 million, with estimates ranging from $40.10 million to $52.60 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $4.72 million. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%.

Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating and set a $5.50 price target on the stock in a research report on Tuesday, August 7th. BidaskClub lowered shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 2nd. ValuEngine lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. Finally, Stifel Nicolaus cut their price target on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, August 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Aratana Therapeutics currently has an average rating of “Buy” and an average target price of $7.96.

In other Aratana Therapeutics news, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction that occurred on Monday, July 30th. The stock was sold at an average price of $4.33, for a total transaction of $49,851.29. Following the sale, the insider now directly owns 649,233 shares in the company, valued at approximately $2,811,178.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ernst Heinen sold 10,372 shares of Aratana Therapeutics stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $5.15, for a total value of $53,415.80. Following the sale, the insider now owns 157,406 shares in the company, valued at $810,640.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 104,187 shares of company stock valued at $595,372. Corporate insiders own 5.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of PETX. American Century Companies Inc. acquired a new position in Aratana Therapeutics during the second quarter valued at $195,000. Bank of Montreal Can grew its stake in Aratana Therapeutics by 152.9% in the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 31,053 shares in the last quarter. Jane Street Group LLC grew its stake in Aratana Therapeutics by 683.0% in the 1st quarter. Jane Street Group LLC now owns 81,952 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 71,486 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Aratana Therapeutics by 23.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 90,100 shares of the biopharmaceutical company’s stock valued at $398,000 after buying an additional 17,300 shares in the last quarter. Finally, Citadel Advisors LLC grew its stake in Aratana Therapeutics by 42.3% in the 1st quarter. Citadel Advisors LLC now owns 97,819 shares of the biopharmaceutical company’s stock valued at $432,000 after buying an additional 29,061 shares in the last quarter. Institutional investors own 65.44% of the company’s stock.

Shares of PETX stock traded down $0.04 on Friday, hitting $5.36. 270,600 shares of the stock traded hands, compared to its average volume of 362,136. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.09. The stock has a market cap of $260.76 million, a price-to-earnings ratio of -5.63 and a beta of 2.37. Aratana Therapeutics has a twelve month low of $3.67 and a twelve month high of $7.28.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: Understanding the different types of bonds

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply